STOCK TITAN

GRAIL (NASDAQ: GRAL) director awarded 329 deferred stock units

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

GRAIL, Inc. director Gregory L. Summe received equity compensation instead of cash fees. On January 15, 2026, he was granted 329 deferred stock units of GRAIL common stock, recorded at a price of $97.44 per share, in lieu of $32,136.98 in cash director fees. These awards vest immediately on the grant date and increase his directly held beneficial position to 39,123 shares of common stock. This filing reflects routine director compensation paid in stock units rather than cash.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SUMME GREGORY L

(Last) (First) (Middle)
C/O GRAIL, INC.
1525 O'BRIEN DRIVE

(Street)
MENLO PARK CA 94025

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GRAIL, Inc. [ GRAL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/15/2026 A 329(1) A $97.44 39,123 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents 329 deferred stock units granted to Mr. Summe under our deferred stock program and 2024 Incentive Award Plan in lieu of $32,136.98 of cash fees payable to Mr. Summe for his service as a director, based on a price per share of $97.44, which was the closing price per share of the Company's common stock on January 15, 2026. The awards will vest immediately upon grant date.
Remarks:
/s/Donald Lang, as Attorney-in-Fact for Gregory Summe 01/16/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did GRAIL (GRAL) report for Gregory L. Summe?

GRAIL reported that director Gregory L. Summe was granted 329 deferred stock units of common stock on January 15, 2026, coded as an acquisition.

What was the value of the deferred stock units granted to the GRAIL director?

The 329 deferred stock units were issued in lieu of $32,136.98 of cash fees, at a reference price of $97.44 per share, based on the closing price on January 15, 2026.

How many GRAIL shares does Gregory L. Summe beneficially own after this Form 4 transaction?

Following the grant, Gregory L. Summe beneficially owns 39,123 shares of GRAIL common stock, held with direct ownership.

Did the GRAIL director’s deferred stock units vest immediately?

Yes. The filing states that the 329 deferred stock units granted to Mr. Summe vest immediately on the grant date.

Why did GRAIL grant deferred stock units instead of paying cash fees to the director?

The 329 deferred stock units were granted in lieu of $32,136.98 of cash fees payable for Gregory L. Summe’s service as a director under GRAIL’s deferred stock program and 2024 Incentive Award Plan.

Is this GRAIL Form 4 transaction a purchase on the open market?

No. The Form 4 describes an equity award of deferred stock units granted as director compensation, not an open-market purchase or sale.

Grail Inc

NASDAQ:GRAL

GRAL Rankings

GRAL Latest News

GRAL Latest SEC Filings

GRAL Stock Data

3.80B
35.08M
13.81%
73.53%
13.42%
Diagnostics & Research
Services-medical Laboratories
Link
United States
MENLO PARK